OBJECTIVE: To probe into the efficacy and economy of cefotaxime sodium sulbactam sodium combined with azithromycin and moxifloxacin in the treatment of community acquired pneumonia（ CAP）

so as to provide suggestions and references for the clinical treatment of CAP. METHODS: Prospective study method was used to collect the data of hospitalized patients with CAP in Nanjing First Hospital

Nanjing Medical University from Jan. to Jun.2019. The observation group（ n = 68） was treated with cefotaxime sodium sulbactam sodium and azithromycin

while the control group（ n = 82） received moxifloxacin. The treatment effects

adverse drug reactions and cost of two groups were observed

and the efficacy and economy were evaluated. RESULTS:（ 1） There were no statistically significant differences in gender

smoking status

use of antibiotics in the past 7 d and types of medical insurance between two groups（ P > 0. 05）

but there were statistically significant differences in age

drinking status and chronic diseases（ P< 0. 05）.（ 2） In terms of clinical efficacy

the effective rate was 91. 2%（ 62/68） in the observation group and91. 5%（ 75/82） in the control group

there was no significant difference between two groups（ P > 0. 05）. Logistic multiple regression model showed that group

gender

age

smoking status

drinking status

chronic disease and use of antibiotics win the past 7 d had no significant effect on the efficacy.（ 3） In terms of length of stay

the length of stay in the observation group was 9（ 8-10） d

and that in the control group was 7（ 6-8） d

there was statistically significant difference between two groups（ P < 0. 05）.（ 4） The incidence of adverse drug reactions in the observation group was 16. 2%（ 11/68）

and that in the control group was 4. 9%（ 4/82）

with statistically significant difference（ P < 0. 05）.（ 5） The total cost of the observation group was 13 608. 76 yuan

and that of the control group was8 399. 53 yuan

the total cost of the control group was significantly lower than that of the observation group

with statistically significant difference（ P < 0. 05）.（ 6） Due to there was no statistically significant difference in the effective rate between two groups（ P > 0. 05）

the minimum cost analysis method was used to directly compare the total cost of two groups for economic evaluation

and the results showed that the control group was more economical.CONCLUSIONS: Cefotaxime sodium sulbactam sodium combined with azithromycin and moxifloxacin is comparable in the treatment of CAP

but moxifloxacin is more cost-effective.